News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,335 Results
Type
Article (47720)
Company Profile (309)
Press Release (691306)
Multimedia
Podcasts (95)
Webinars (12)
Section
Business (214135)
Career Advice (2288)
Deals (37327)
Drug Delivery (118)
Drug Development (85334)
Employer Resources (178)
FDA (16891)
Job Trends (15824)
News (363572)
Policy (34961)
Tag
Academia (2715)
Accelerated approval (5)
Adcomms (26)
Allergies (92)
Alliances (52507)
ALS (97)
Alzheimer's disease (1421)
Antibody-drug conjugate (ADC) (144)
Approvals (16878)
Artificial intelligence (277)
Autoimmune disease (27)
Automation (16)
Bankruptcy (380)
Best Places to Work (12025)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (194)
Bladder cancer (80)
Brain cancer (30)
Breast cancer (287)
Cancer (2359)
Cardiovascular disease (196)
Career advice (1907)
Career pathing (33)
CAR-T (165)
Cell therapy (454)
Cervical cancer (20)
Clinical research (69293)
Collaboration (883)
Company closure (1)
Compensation (548)
Complete response letters (28)
COVID-19 (2726)
CRISPR (47)
C-suite (253)
Cystic fibrosis (105)
Data (2243)
Decentralized trials (2)
Denatured (29)
Depression (50)
Diabetes (288)
Diagnostics (6558)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (126)
Drug pricing (121)
Drug shortages (32)
Duchenne muscular dystrophy (96)
Earnings (89110)
Editorial (44)
Employer branding (22)
Employer resources (153)
Events (118769)
Executive appointments (749)
FDA (18186)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (778)
Gene editing (116)
Generative AI (24)
Gene therapy (328)
GLP-1 (811)
Government (4710)
Grass and pollen (5)
Guidances (67)
Healthcare (19584)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (137)
Indications (30)
Infectious disease (2881)
Inflammatory bowel disease (146)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (99)
Interviews (353)
IPO (17031)
IRA (48)
Job creations (4219)
Job search strategy (1634)
Kidney cancer (11)
Labor market (38)
Layoffs (515)
Leadership (23)
Legal (8651)
Liver cancer (76)
Lung cancer (332)
Lymphoma (158)
Machine learning (7)
Management (61)
Manufacturing (333)
MASH (72)
Medical device (13683)
Medtech (13688)
Mergers & acquisitions (20845)
Metabolic disorders (761)
Multiple sclerosis (85)
NASH (20)
Neurodegenerative disease (103)
Neuropsychiatric disorders (34)
Neuroscience (2004)
NextGen: Class of 2025 (6906)
Non-profit (4755)
Now hiring (39)
Obesity (413)
Opinion (255)
Ovarian cancer (77)
Pain (99)
Pancreatic cancer (84)
Parkinson's disease (157)
Partnered (21)
Patents (244)
Patient recruitment (114)
Peanut (50)
People (60547)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21569)
Phase II (30393)
Phase III (22790)
Pipeline (1237)
Policy (165)
Postmarket research (2808)
Preclinical (9176)
Press Release (68)
Prostate cancer (112)
Psychedelics (31)
Radiopharmaceuticals (261)
Rare diseases (417)
Real estate (6449)
Recruiting (67)
Regulatory (23820)
Reports (46)
Research institute (2446)
Resumes & cover letters (384)
Rett syndrome (5)
RNA editing (5)
RSV (48)
Schizophrenia (78)
Series A (137)
Series B (88)
Service/supplier (14)
Sickle cell disease (58)
Special edition (17)
Spinal muscular atrophy (154)
Sponsored (30)
Startups (3832)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (46)
The Weekly (64)
Vaccines (743)
Venture capitalists (41)
Weight loss (291)
Women's health (36)
Worklife (18)
Date
Today (137)
Last 7 days (930)
Last 30 days (2708)
Last 365 days (33876)
2025 (11130)
2024 (36397)
2023 (41228)
2022 (52441)
2021 (57069)
2020 (55698)
2019 (48651)
2018 (36784)
2017 (33974)
2016 (33771)
2015 (39622)
2014 (33577)
2013 (28791)
2012 (30913)
2011 (31627)
2010 (29938)
Location
Africa (840)
Alabama (53)
Alaska (7)
Arizona (242)
Arkansas (14)
Asia (42274)
Australia (6783)
California (6206)
Canada (2036)
China (553)
Colorado (271)
Connecticut (277)
Delaware (153)
Europe (91286)
Florida (931)
Georgia (208)
Idaho (58)
Illinois (565)
India (26)
Indiana (322)
Iowa (11)
Japan (169)
Kansas (106)
Kentucky (25)
Louisiana (10)
Maine (62)
Maryland (921)
Massachusetts (4697)
Michigan (227)
Minnesota (396)
Mississippi (2)
Missouri (83)
Montana (31)
Nebraska (25)
Nevada (64)
New Hampshire (65)
New Jersey (1765)
New Mexico (31)
New York (1768)
North Carolina (1031)
North Dakota (8)
Northern California (2706)
Ohio (208)
Oklahoma (14)
Oregon (40)
Pennsylvania (1393)
Puerto Rico (13)
Rhode Island (34)
South America (1257)
South Carolina (23)
South Dakota (1)
Southern California (2320)
Tennessee (104)
Texas (923)
United States (23655)
Utah (184)
Virginia (156)
Washington D.C. (63)
Washington State (564)
West Virginia (3)
Wisconsin (57)
739,335 Results for "mt pharma america inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Mitsubishi Tanabe Pharma America Presents Final Results from the Global, Phase 3b MT-1186-A02 Post-marketing Study of RADICAVA® (edaravone) in ALS
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of final results from the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in amyotrophic lateral sclerosis (ALS).
June 17, 2024
·
7 min read
Pharm Country
Mitsubishi Tanabe Pharma America, Inc. (MTPA) Stands with the ALS Community
Mitsubishi Tanabe Pharma America, Inc. is aware of recent external challenges facing the amyotrophic lateral sclerosis treatment landscape.
May 23, 2024
·
6 min read
Press Releases
Mitsubishi Tanabe Pharma America to Highlight Latest Advances in Neurodegenerative Research at the American Academy of Neurology 2025 Annual Meeting
April 3, 2025
·
10 min read
Press Releases
Mitsubishi Tanabe Pharma America Announces Publication of Preclinical Research on the Role of Edaravone in Mitigating TDP-43 Mislocalization in ALS
March 26, 2025
·
4 min read
Press Releases
Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting
April 30, 2025
·
7 min read
Press Releases
Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference
March 12, 2025
·
9 min read
Press Releases
Mitsubishi Tanabe Pharma America to Share Latest Data on Investigational ND0612 at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)
April 1, 2025
·
4 min read
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
Press Releases
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
April 29, 2025
·
7 min read
Pharm Country
Mitsubishi Tanabe Pharma America Celebrates Second Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the two-year launch anniversary of RADICAVA ORS ® (edaravone) in the U.S.
June 17, 2024
·
10 min read
1 of 73,934
Next
